

**AMENDMENT**

**OFFERED BY MR. SCHRADER OF OREGON**

In the section 1192 of the Social Security Act proposed to be added by section 101(a)—

(1) in subsection (b), insert “, taking into account the recommendations (if any) from the selection advisory committee established under subsection (g),” after “the Secretary projects”; and

(2) add at the end the following new subsection:

1 “(g) SELECTION ADVISORY COMMITTEE.—

2 “(1) IN GENERAL.—Not later than 1 year after  
3 the date of the enactment of this Act, the Secretary  
4 shall establish a selection advisory committee for  
5 purposes of making recommendations to the Secretary relating to the selection and publication of negotiation-eligible drugs under subsection (a)(1) and  
6 the projection of savings with respect to such drugs  
7 under subsection (b) for initial price applicability  
8 years beginning with plan year 2024.

11 “(2) COMPOSITION.—The committee described  
12 in paragraph (1) shall be composed of members selected by the Secretary and shall include at least the  
13 following:  
14

1           “(A) 1 practicing physician and 1 prac-  
2           ticing pharmacist with expertise in the care of  
3           1 or more specific populations, such as elderly  
4           or disabled individuals, children with complex  
5           medical needs, or low-income individuals with  
6           chronic illnesses.

7           “(B) 1 representative from a group health  
8           plan or health insurance issuer (as such terms  
9           are defined in section 2791 of the Public  
10          Health Service Act).

11          “(C) 1 representative from a manufacturer  
12          of a single source drug.

13          “(D) 1 representative from a manufacturer  
14          of a generic drug.

15          “(E) 1 representative from a manufacturer  
16          of a biological product.

17          “(F) 1 representative from a manufacturer  
18          of a biosimilar biological product.

19          “(G) Any other individual determined ap-  
20          propriate by the Secretary.

21          “(3) CONFLICT OF INTEREST POLICY.—The  
22          Secretary shall establish conflict of interest require-  
23          ments with respect to members of the committee de-  
24          scribed in paragraph (1) that—

25                 “(A) are publicly available;

1           “(B) require all such members to complete,  
2           not less frequently than annually, a disclosure  
3           of any relationships, associations, or financial  
4           dealings that may affect such members’ inde-  
5           pendence of judgement in making recommenda-  
6           tions described in such paragraph;

7           “(C) contain clear processes, such as  
8           recusal from voting or discussion, for such  
9           members who report a conflict of interest with  
10          respect to making such recommendations, along  
11          with appropriate processes to address any in-  
12          stance where a member fails to report a conflict  
13          of interest; and

14          “(D) ensure that any member described in  
15          subparagraph (A) of paragraph (2) is free from  
16          conflicts of interest with respect to drug manu-  
17          facturers, prescription drug plans under part D  
18          of title XVIII, and MA-PD plans under part C  
19          of such title.”.

